Home / Business and Economy / Pharmacy Fights Court Ban on Weight-Loss Drugs
Pharmacy Fights Court Ban on Weight-Loss Drugs
14 Jul
Summary
- iDexis is appealing a court order restricting its weight-loss drug production.
- Regulators cited safety and compliance issues during facility inspections.
- The pharmacy disputes regulators' findings, citing independent test results.
South African pharmacy group iDexis has applied to appeal a court judgment that significantly restricted its manufacturing of compounded weight-loss drugs. This action follows an interim High Court order granted last month, which prohibited iDexis from producing and selling GLP-1 medicines containing semaglutide. The legal challenge was initiated by Novo Nordisk amid increased scrutiny of compounded versions of popular weight-loss and diabetes treatments.
During a joint inspection in May, regulators SAHPRA and SAPC found that iDexis was producing GLP-1 medicines for commercial distribution beyond regulatory limits. They also identified serious deficiencies in quality, safety, and compliance, leading to the seizure of products and a recall order. iDexis disputes these findings, stating that independent testing commissioned by the company found no evidence of sterility breaches and confirmed the products' safety and appropriate compounding procedures.
In addition to appealing the court order, iDexis has lodged separate appeals against the regulators' findings and decisions. The company's managing director expressed concern about being singled out, suggesting other pharmacies may be producing similar products. iDexis intends to pursue legal remedies against the regulators if internal appeals are exhausted, aiming to clear its name and restore its reputation in the compounding pharmacy sector.
